NCT01357655 - Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Leukemia

Interventions

DRUG

Dasatinib

Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response

DRUG

BMS-833923

Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response

Trial Locations (24)

2060

Local Institution, Antwerp

4000

Local Institution, San Miguel de Tucumán

28006

Local Institution, Madrid

28034

Local Institution, Madrid

31008

Local Institution, Pamplona

31059

Local Institution, Toulouse

33006

Local Institution, Oviedo

33076

Local Institution, Bordeaux

37203

Tennessee Oncology Pllc, Nashville

44000

Local Institution, Nantes

59037

Local Institution, Lille

67091

Local Institution, Strasbourg

75475

Local Institution, Paris

78150

Local Institution, Le Chesnay

84112

Huntsman Cancer Institute, Salt Lake City

07601

John Theurer Cancer Center, Hackensack

B-8000

Local Institution, Bruges

T6G 1Z2

Local Institution, Edmonton

00290

Local Institution, Helsinki

41-500

Local Institution, Chorzów

80-952

Local Institution, Gdansk

30-510

Local Institution, Krakow

93-513

Local Institution, Lodz

50-367

Local Institution, Wroc#aw